Search results for "From ACP Journal Club"
April 28, 2017 | ACP Gastroenterology Monthly
ACP Gastroenterology Monthly delivers a monthly summary of news in gastroenterology and hepatology, including the latest research, clinical guidelines, and FDA drug actions.
Colonoscopy outreach increased CRC screening more than FIT outreach; both were better than usual care | ACP Gastroenterology Monthly
Those choosing screening tests may need to start considering the feasibility of achieving all related downstream actions as well as sensitivity, false-positive rates, safety, and cost, an ACP Journal Club commentary said.
In primary biliary cholangitis, adding bezafibrate to ursodeoxycholic acid increased complete biochemical response | ACP Gastroenterology Monthly
Bezafibrate is currently unavailable in the U.S., but fenofibrate can be offered off-label in these patients with close monitoring of adverse effects, an ACP Journal Club commentary said.
January 26, 2018 | ACP Gastroenterology Monthly
ACP Gastroenterology Monthly delivers a monthly summary of news in gastroenterology and hepatology, including the latest research, clinical guidelines, and FDA drug actions.
February 24, 2017 | ACP Gastroenterology Monthly
ACP Gastroenterology Monthly delivers a monthly summary of news in gastroenterology and hepatology, including the latest research, clinical guidelines, and FDA drug actions.
January 27, 2017 | ACP Gastroenterology Monthly
ACP Gastroenterology Monthly delivers a monthly summary of news in gastroenterology and hepatology, including the latest research, clinical guidelines, and FDA drug actions.
October 26, 2018 | ACP Gastroenterology Monthly
ACP Gastroenterology Monthly delivers a monthly summary of news in gastroenterology and hepatology, including the latest research, clinical guidelines, and FDA drug actions.
Review: In chronic hepatitis C virus infection, oral direct-acting antivirals have high sustained virologic response | ACP Gastroenterology Monthly
A commentary in ACP Journal Club noted that while screening and treating all patients with chronic hepatitis C virus (HCV) would be cost-effective and probably cost-saving, some payers are still resistant.
In Barrett esophagus, high- vs low-dose esomeprazole improved clinical outcomes; aspirin vs no aspirin did not | ACP Gastroenterology Monthly
The safety of high-dose proton-pump inhibitor therapy is probably acceptable, but the addition of aspirin carries more risk, has less evidence on efficacy, and needs an individualized approach, an ACP Journal Club commentary said.
In IBS with constipation, plecanatide reduced abdominal pain and increased bowel movements at 12 wk | ACP Gastroenterology Monthly
Clinical judgment will be needed to determine whether the relatively modest improvement in outcomes will be important to patients for whom the drug is considered, according to an accompanying ACP Journal Club commentary.